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24 N. Mulder et al. / Applied & Translational Genomics 9 (2016) 23–29disparate efforts. Ensuring data across studies is directly comparable through standardization is a necessary step
towards realizing this goal. Such a standardization requires the development and implementation of a disease-
specific ontology for SCD that is applicable globally. Ontology development is best achieved by bringing together
experts in the domain to contribute their knowledge.
The SCD community and H3ABioNet members joined forces at a recent SCD Ontology workshop to develop an
ontology covering aspects of SCD under the classes: phenotype, diagnostics, therapeutics, quality of life, disease
modifiers and disease stage. The aim of the workshopwas for participants to contribute their expertise to devel-
opment of the structure and contents of the SCD ontology. Here we describe the proceedings of the Sickle Cell
Disease Ontology Workshop held in Cape Town South Africa in February 2016 and its outcomes. The objective
of the workshop was to bring together experts in SCD from around the world to contribute their expertise to
the development of various aspects of the SCD ontology.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background and motivation
Sickle cell disease (SCD) is themost common single gene disorder in
the world. It is caused by a single point mutation (Gluβ6Val) that
promotes polymerization of hemoglobin (Hb) S and physical deforma-
tion (i.e. sickling) of erythrocytes at reduced oxygen tensions. SCD
manifests in multiple phenotypes, including inflammation, hemolysis,
micro- and macrovascular obstruction and organ damage. Multiple
genetic and environmental factors influence the pathophysiological
aspects of SCD that contribute to a highly variable clinical expression
in individual patients. It is estimated that 305,800 babies are born
worldwide annually with homozygous SCD (SCD-SS), with nearly 75%
of hemoglobin SS births occurring in sub-Saharan Africa (SSA) (Piel
et al., 2013). Despite this high incidence, life-saving public health
programs have not been implemented in most SSA countries, often
due to limited health care resources and infrastructures. As a
consequence, neonatal and childhoodmortality due to sickle cell related
complications remains high, and estimates suggest that without inter-
vention, up to 90% of affected children in SSA die by five years of age
from SCD (Grosse et al., 2011; Fleming et al., 1979).
Despite numerous SCD research efforts across the globe, integration
and coordination of these efforts are lacking and a measureable impact
on patient care has yet to be realized. In sharp contrast to SSA, compre-
hensive clinical care programs in high-income nations like the US
have reduced SCD-related early childhood deaths by 70% (Yanni et al.,
2009; Vichinsky, 1991). Nonetheless, adults with SCD in high-income
countries continue to die at a high rate as a consequence of additional
debilitating complications (Chaturvedi and DeBaun, 2016, Hamideh
and Alvarez, 2013, McClellan et al., 2012; Shankar et al., 2005) and
have poor quality of life (Keller et al., 2014; Ameringer et al., 2014;
Anie et al., 2012, Dampier et al., 2011).
There is amajor need for research on large cohorts of comprehensive-
ly and consistently phenotyped SCD patients to help develop effective
therapies across the life span for SCD patients in all parts of the world,
particularly in Africa. Despite the high SCD prevalence in SSA nations,
most of these regions are short of the resources, infrastructure and ca-
pacity required to perform epidemiological, translational, and clinical re-
search. Nonetheless, research on an adequately phenotyped large cohort
of SCD patients in Africa is necessary to achieve this goal. This, together
with establishing public health care infrastructures, and an appropriate
management strategy, has the potential to reduce childhood mortality
and improve patient quality of life.
Coordination of research activities on different patient cohorts
requires development of a Sickle Cell Ontology that provides a
controlled and consistent vocabulary of various definitions of SCD in
terms of clinical events, genetic and environmental modifiers,
co-morbidities, therapeutics, psychosocial burden and quality of life.
Such an ontology, ultimately linked to standard protocols for assessing
phenotypes and interventions, will inform the standardized collection
of data in large cohort studies, as well as surveillance systems which
phenotype and follow up patients and families affected by SCD.Previous work in this area has focused on standardization of SCD
complications or phenotypes (Ballas et al., 2010), disregarding other
aspects pertinent to this domain such as diagnostics. These attempts
suffer from several limitations, which were pointed out by an indepen-
dent commentary (DeBaun, 2010) and include lack of a reliablemethod
to reach consensus agreements on terms and their descriptions, and
imprecise definitions which failed to differentiate between similar
but distinct phenotypes.The Sickle Pan African Network (SPAN)
and H3ABioNet, a Pan African Bioinformatics Network for H3Africa
(H3ABioNet: Mulder et al., 2015) joined forces to lead the development
of an improved SCD Ontology, which aims to address the informational
gap in the Sickle Cell Disease field. Specifically it aims to:
● establish community standardized SCD terms and descriptions;
● establish canonical and hierarchical representation of knowledge on
SCD;
● work collaboratively with PhenX (consensus measures for
Phenotypes and eXposures: Hamilton et al., 2011) to establish
standard protocols for assessing SCD phenotypes in limited
resource populations.
In this paper, we describe the development of the ontology, culmi-
nating in an ontology development workshop. The workshop was
truly international, including participants from the United Kingdom,
United States of America, Brazil, Jamaica, Kuwait and eleven African,
countries. Most of the workshop participants were invited based on
their SPAN membership, and the rest of the international delegation
was invited based on their knowledge in ontologies or SCD and involve-
ment in SCD consortia, networks and clinics. Of those invited, thirty six
were able to attend, and included expertise in SCD, ontologies and
bioinformatics. Workshop outcomes were measured by changes in the
state of the ontology before and after the workshop. In addition, the
workshop was evaluated by administering a survey for participants. A
set of recommendations for developing a disease-specific ontology
were developed.
2. Ontology development process
To spearhead the creation of the ontology, a working group was
established via collaboration between SCD experts (mostly from the
SPAN) and H3ABioNet members. A Harmonization Center (including
curators and developers)was created to facilitate the ontology develop-
ment, and a panel of ontology expertswas established to ensure that the
ontology was developed based on established good practices. The
ontology expert panel consisted of members from the European
Bioinformatics Institute (EBI) Ontology Group and the Open Biological
and Biomedical Ontologies (OBO) Foundry. An iterative ontology devel-
opment process (illustrated in Fig. 1) was implemented, involving
stakeholder engagement and several community based activities facili-
tated by the working group. Engagement with stakeholders involved
Fig. 1. Overview of the development process.
(Process adapted from Noy & McGuiness, 2001.)
25N. Mulder et al. / Applied & Translational Genomics 9 (2016) 23–29discussions with PhenX project participants to obtain specific terms as-
sociated with measures in the PhenX Toolkit (https://www.
phenxtoolkit.org/). The EBI contributed phenotype terms cataloged
from published text mining tools run against a set of popular SCD-
related journals, and H3ABioNet set up WebProtégé (Horridge et al.,
2014) for editing the ontology.
Community based activities included meetings with SCD experts;
a face-to-face project initiation meeting was held in Livingstone,
Zambia, on 11th May 2015, followed by continued online consultations
and meetings. A second formal meeting was held during the 7th H3-
Africa consortiummeeting inWashington, DC,where the draft ontology
was discussed, and most recently, an ontology development workshop
was held in Cape Town.
3. Workshop proceedings
In February 2016, the Sickle Cell Disease Ontology (SCDO) working
group hosted a SCDO workshop. The objective of the workshop was to
bring together experts in SCD from around the world to contribute
their expertise to the development of various aspects of the SCD
ontology. The meeting was attended by 36 participants, including
clinicians, geneticists, psychologists and bioinformatics researchers.
Sixteen countries, most of which have a high prevalence of SCD, had
at least one representative at the workshop. The first day of the
workshop was intended to provide background to the participants on
ontologies and SCD.
The meeting commenced with a keynote presentation by Professor
Kwaku Ohene-Frempong, who gave an overview of SCD and how it is
perceived and named traditionally in different parts of Africa. The histo-
ry of Sickle Cell Disease was also highlighted in this keynote, from the
discovery of sickle cells by Dr. Ernest Irons on patient Walter Clement
Noel in December 1904 (Herrick, 1910; Savitt, 2010) to the coining of
the term “Sickle” by Von M. Lowit in 1905 (Löwit, 1905). The lack of
standardized terms in this domain and confusion between the disease
and the trait were highlighted. Professor Ohene-Frempong further
described how the sickling testmay cause confusion around the disease
and demonstrated how some medical professionals are not sufficiently
educated to effectively treat patients affected with SCD. The keynote
was followed by talks introducing the concept of ontologies, how they
are created, best practices, and some example ontologies used in the
biomedical domain.
The scope of the ontology was based on a draft ontology and on
potential use case questions developed via group work. The draft SCDontology, which had been developed by the Harmonization Center
and reviewed by the SCD Ontology working group during H3Africa
consortium meetings in Zambia and in Washington, was presented to
the participants at this meeting.
Workshop participants were allocated into groups to work on
specific classes and sub-classes based on their expertise using the
draft ontology as a starting point. Chairs and rapporteurs were allocated
to each group.
Once theworkshop participants understood the value of creating an
ontology, working groups began by defining use case questions. Some
example questions were:
● What are the procedures and instruments used for diagnosing
patients with SCD with pulmonary hypertension?
● What are the possible adverse effects of treating a pediatric patient
with hydroxyurea?
● What is vitreous hemorrhage, and how is it diagnosed and man-
aged?
● What phenotypes are observedwhen a patient co-inherits sickle cell
anemia (SCA) and beta thalassemia?
The second and third days of the workshop focused on group-work
aimed at defining the terms and reviewing the sub-classes. The ontolo-
gy was developed under the following main classes: phenotype,
diagnostics, therapeutics, quality of life, disease modifiers (genetic and
environmental), and disease stage. Several sources of terms were
used for the ontology, these include: SCD experts (electronically and
at the workshop), text mining of abstracts using Whatizit (Rebholz-
Schuhmann et al., 2008), existing PhenX terms for SCD, Medical
Subjects Headings (MeSH), the National Institute of Health and Care
Excellence (NICE), World Health Organization (WHO) reports, the Pa-
tient Reported OutcomesMeasurements Information System (PROMIS)
domains (Cella et al., 2010), scientific literature andmining existing on-
tologies using the EMBL-EBI Ontology Lookup Service (OLS) (Côté et al.,
2010).WebProtégéwas the tool of choice to collaboratively develop the
SCDO and was prepopulated with some of the existing terms curated to
date. WebProtégé is an open-source Web application for designing and
editing ontologies, which offers several features which permit collabo-
rative development and editing within communities, and has a simple
user-friendly interface (Horridge et al., 2014). Some groups chose to
continue working inWebProtégé, others used spreadsheets, alternative
electronic tools or flip charts.
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by each group, followed by a discussion of possible applications of the
ontology, and future plans and projects for both the ontology and the
working group. An existing SCD database was presented, along with
REDCap (Research Electronic Data capture) as an option for an integrat-
ed SCD resource. REDCap (Harris et al., 2009) is a secure, web-based
application for managing online databases and surveys. It provides
multiple sites real-time access to data, while minimizing the logistical
challenges in conducting multi-center collaborative projects. REDCap
also offers mechanisms for secure storage, validation and reporting of
data.
4. Workshop outputs
4.1. SCD ontology development
The workshop participants were committed to the ontology
development and lively discussions took place during group work.
The ontology was extended most significantly in the fine-tuning of
the structure and adding annotations/features to terms. The major
changes in the different classes of the draft ontology captured in
WebProtégé before and after the workshop are summarized in Table 1.
The Sickle Cell experts at theworkshopmade recommendations that
affected the structure and the contents of the ontology in the following
ways: 1) Class Renaming: renaming occurs when a class or a property
retains the definition and properties that it had prior to the workshop
but the name of the class is changed; 2) Inclusion of Additional Annota-
tion: some annotations were added to clarify information that was
contained in the properties. For example, the prefLabel annotation
property was added in some classes to resolve naming conflicts,
where clinicians had preferred names that differed from ontology
terms; 3) Gap-filling alterations: these were made in cases where there
was pending data to cover already defined classes and properties. For
example, many definitions lacked quality references before the work-
shop and were tagged with badd sourceN in places where a reference
was expected; 4) Complete Redefinition: this is when a new sub-class
or property was defined within a class that previously existed in the
ontology version before the workshop. An example of changes to the
Diagnostics class is shown in Fig. 2.
4.1.1. Summary reports from the Groups
4.1.1.1. Group I & Group II – Class: Phenotypes. This groupwas challenged
to define clinical terms commonly used in the clinical manifestations of
SCD. 1797 termswere extracted from the EBI text mining procedure. Of
the 1797 terms reviewed, 1012 terms were approved by the respective
experts. Multiple terms were synonyms of each other and these wereTable 1
Summary of major changes of metrics in WebProtégé before and after the workshop.
Metric Class Sub-class
Phenotype Description was added. The experts deleted the tw
(Proxy Phenotypes and Re
classification system simila
structures was used instea
Modifiers The name was changed from
Genetic Modifiers to Modifiers.
Extra sub-classes were add
Environmental modifiers.
class was relegated to a su
structures were changed t
Diagnostics Description was added. New sub-classes were imp
ontologies.
Quality of life Quality of life was split into
two classes: Quality of life
and Quality of care.
New subclasses were adde
Quality of care A new class was created to cater
for quality of care.
Five sub-classes were defin
Therapeutics Description was added The Abortive sub-class wa
sub-class of Alternative thcombined into the most commonly accepted term, as decided by the
working group. Six terms have subsequently been added. These terms
were classified into the respective systems outlined previously by the
working group members. Hematopoeitic, Urinary, Pulmonary,
Neurologic, Cardiovascular, Immune, and Musculoskeletal, were
among the 18 systems used as “clinical buckets” for their terms. Some
of the definitions referenced previously defined terms in publications
including the NHLBI 2014 Sickle Cell Disease Evidence Based Guidelines
(Yawn et al., 2014) and the Phenotypic Definitions of Sickle Cell Disease
publication from United States Comprehensive Sickle Cell Centers
(Ballas et al., 2010).
4.1.1.2. Group III – Class: Modifiers. This group suggested differentiating
between genetic and environmental modifiers. In addition, this group
was tasked with defining the SCD and sickle cell trait. Prior to the start
of the workshop, only 4 terms had been defined in this class, and after
the workshop this class had 41 terms.
4.1.1.3. Group IV – Class: Diagnostics. Diagnostic procedures used by SCD
experts were captured in this class. Most terms in this class were
imported from PhenX and existing biomedical ontologies. Discussions
included use of terms such as “assay” versus “test”. It was agreed to
use preferred terminology and use the community recommended
ontology terms as synonyms.
4.1.1.4. Group V – Class: Quality of Life and Quality of Care. This groupwas
tasked with defining and standardizing terms in relation to psychologi-
cal, socio-economic and health care related factors associated with the
burden of SCD on affected individuals and their families. Over 60
terms were added within the Quality of Life (QoL) and Quality of Care
(QoC) classes. Cross-referencing with other groups was discussed, for
example, the potential contributions of socio-economic factors and
stress to disease manifestations. A list of psychological and behavioral
therapies was shared with the Therapeutics group. Outstanding work
includes documenting standard, valid and reliable generic or disease-
specific instruments that could be used to capture QoL and QoC
information, including measures that can be found in the PhenX toolkit
– Sickle Cell Disease Neurology, Quality of Life, and Health Services
Specialty Collection. The group will cross-reference clinical symptom-
atology that has been cited as impacting QoL using the glossary from
the National Heart, Lung and Blood Institute Evidence Based Manage-
ment of Sickle Cell Disease (http://www.nhlbi.nih.gov/health-pro/
guidelines/sickle-cell-disease-guidelines), and will also cross-reference
the pain descriptors with the Phenotype group.
4.1.1.5. Group VI – Class: Therapeutics. This group focused on the
sub-classes related to therapeutic interventions that are alreadyTerms
o sub-classes in the draft
lated Complications). A
r to the Disease ontology
d.
Most terms did not have properties before the
workshop.
ed including
The Genetic Modifiers
b-class. The sub-class
o have deeper branches.
New terms were added to this class.
orted from existing Extra terms were imported from existing
biochemical assays.
d. Terms were adapted from existing vocabularies
and reputable sources (references were included).
Standard measures were also included.
ed under quality of care. Terms were adapted from existing vocabularies
and reputable sources (references were included).
s removed and a new
erapies was added.
Terms were defined under each.
Fig. 2. A snapshot of part of the Diagnostics class from the SCD Ontology in WebProtégé before (a) and after (b) the workshop.
27N. Mulder et al. / Applied & Translational Genomics 9 (2016) 23–29available inWebProtégé. The aimwas to identify the different branches
that could be associated with each therapeutic class. During the discus-
sion, the group decided to keep the Curative, Preventive, Symptomatic
sub-classes, but changed the name of the Supportive sub-class to
Supportive/Complementary. They also added a new sub-class named
Alternative Therapies and removed the Abortive sub-class. The contents
of the Abortive sub-class were moved to the other sub-classes as
appropriate.
4.1.1.6. Group VII – Class: Disease stage. Staging of the SCD is still under
discussion and is likely to be concluded during the final stages of the
development of the ontology. Discussions around staging highlighted
the need to differentiate between sporadic, acute, mild, chronic and
progressive dysfunction events. Acute events were agreed to be more
dangerous, largely unpredictable, and to be the leading cause of mortal-
ity among SCD patients. Next steps include reviewing and curating eachSCD phenotype with the appropriate disease stage term, where
appropriate.
4.2. Workshop recommendations
To finalize the SCD ontology, workshop participants agreed to
continue reviewing terms independently after the workshop and
make them accessible to their working group for final review. Skype
meetings, Google docs and WebProtégé will be used to facilitate the
collaborative work going forward. It was also agreed that a face-to-
face meeting would be essential to conclude a major section of the
work. Once the ontology is finalized, which is expected to be by
September 2016, existing SCD data which is comprehensively
phenotyped from 2 to 3 different sites in Africa will be used to assess
the ontology for coverage and accuracy. The future plan is also to create
a standardized case reporting form (CRF) for SCD patient recruitment,
28 N. Mulder et al. / Applied & Translational Genomics 9 (2016) 23–29which can be mapped to the ontology and to standard measures
(Hendershot et al., 2015).
Based on our experiences and feedback from workshop, we would
like to recommend the following plan for building any disease-specific
ontology:
• Establish a collaboration between bioinformaticians and disease
experts.
• Create a working group to drive the process, and a harmonization
center to bring together the ontology work.
• Secure funding for the ontology development and relevant workshops.
• Set milestones with due dates as most contributors are contributing on
a voluntary basis. Ensure a mechanism is in place to monitor achieve-
ment of milestones.
• Decide on a mechanism for creating, sharing and editing the ontology
from multiple sites. Set up a website to host the ontology and related
information.
• Organize aworkshop (we recommend a fullweek for suchworkshops),
divide contributors into sub-groups based on their speciality. Transla-
tors should be made available.
• Make the workshop and subsequent work as participatory as possible
including the planning of the workshop. Set up an emailing list to facil-
itate communication, continue with ontology development online and
provide regular feedback.
• Use real datasets from the community to test the ontology for coverage
and accuracy. Encourage the community to start applying the ontology
to their datasets and to provide feedback.
• Establish a plan for how to update/modify the ontology as our
knowledge base changes over time.
• Have plans in place to disseminate the workshop proceedings in
preparation of the releasing of the ontology, through publications and
reports. Report on progress regularly to contributors, funders and
other stakeholders.
4.3. Workshop evaluation
A surveywith four closed and two open questionswas administered
to workshop participants in order to evaluate the success of the work-
shop. Twenty-five out of thirty six participants gave anonymous feed-
back which is summarized in Table 2. Most participants (88%, n = 25)
reported intending to use the SCDO. Over 90% of the participantsTable 2
Feedback from 25 workshop participants.
Closed questions
When did you first learn about ontologies?
Do you intend to continue being an active member of the
Sickle Cell Disease Ontology working group?
Do you plan on using the Sickle Cell Disease ontology
for your own work?
Please rate the workshop logistics.
Open ended questions Selected quotes
What did you like the most about the workshop? “Well organized, expert
“The SCDO workshop en
particular SCD”
What changes would you suggest for future ontology
development workshops?
“Stronger internet conn
“I am overall satisfied w
specialists for future wointended to continue being active members of the SCDO working
group. Most of the participants recommended longerworkshops, better
internet connection and translations into French. The participants
reported liking the collaborative nature of the workshop, leadership,
experts gathered and the productiveness of the workshop. More than
half of the participants first learnt about ontologies from the workshop
organizers.5. Conclusions
The SCD Ontology workshop brought together thirty six experts in
SCD from all over the world. The enthusiasm and active participation
of all attendees was noticeable and infectious. The key challenge will
be to maintain this momentum to enable completion and implementa-
tion of the ontology. Once completed, we anticipate that the ontology
will be the most comprehensive collection of knowledge in the SCD
field. It will be used to facilitate exploring of new scientific questions
and ideas; to facilitate seamless data sharing and collaborations
including meta-analysis within the SCD community; and to support
the development and curation of databases and clinical informatics in
SCD. Most importantly, it is hoped that the ontology will be used to
share data among the SCD community, and enable queries across the
different datasets. In addition, we hope that the SCD ontology can
serve as a model for other disease communities wishing to establish
their own ontology.Acknowledgments
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